California
“10-K Item 1A: 'Our operations are concentrated in one location ... Our current operations are predominantly located in California.'”
Updated
The most significant concentration Xencor discloses is California, classified HIGH by disclosed size. Below: the full set from the latest 10-K — verbatim quotes, filing references, and a synthesis of what these exposures mean together.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Source: Xencor’s SEC Form 10-K filed — view the filing on SEC EDGAR ↗
Each card carries a disclosed-size chip (HIGH / MEDIUM / LOW — how large the exposure is as a share of revenue, not how dangerous it is) and a nature tag: Built-in(the company’s own model, geography, or products) or Outside party (an external customer, supplier, or distributor it relies on).
“10-K Item 1A: 'Our operations are concentrated in one location ... Our current operations are predominantly located in California.'”
Xencor's disclosed concentration risk is singular and structural: the company states that its operations are concentrated in one location, with current operations predominantly located in California, a high-share geographic exposure. Unlike concentration built around a specific customer, supplier, or licensing counterparty, this exposure is tied to where the company's facilities physically sit, meaning a regional disruption — whether a natural disaster, a labor market shift, or a state-level regulatory change — could affect the entirety of Xencor's operations rather than a single product line or relationship. Because it is the only concentration exposure disclosed and it touches the whole business rather than a piece of it, it is also the exposure most capable of moving the verdict on its own: there is no offsetting diversification across other manufacturing sites, customers, or geographies to point to. Investors should treat this single-location structural exposure as the primary lens through which to assess Xencor's operational resilience, recognizing that it is a facility-and-labor-market risk rather than a counterparty risk, and that remediating it would require years of investment in additional sites rather than a near-term contractual change.
For the engine’s reasoning on XNCR’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.
| Symbol | Name | HIGH | MEDIUM | LOW | Total |
|---|---|---|---|---|---|
| ACAD | ACADIA Pharmaceuticals Inc. | 2 | 0 | 0 | 2 |
| ABUS | Arbutus Biopharma Corporation | 1 | 1 | 0 | 2 |
| ABSI | Absci Corporation | 1 | 0 | 0 | 1 |
| XNCR● | Xencor, Inc. | 1 | 0 | 0 | 1 |
| ABCL | AbCellera Biologics Inc. | 0 | 0 | 0 | 0 |
| ACHV | Achieve Life Sciences, Inc. | 0 | 0 | 0 | 0 |
Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.